SELLAS Life Sciences Group Inc Dossier
Qualitative Analysis
Business overview
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent targeting the Wilms tumor 1 (WT1) protein, which is licensed from Memorial Sloan Kettering Cancer Center. GPS is currently being evaluated in the pivotal Phase 3 REGAL trial for patients with acute myeloid leukemia (AML) who are in second-line complete remission. The second key asset in SELLAS's pipeline is SLS009 (formerly GFH009), a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which is advancing in Phase 2 clinical trials for hematologic malignancies, including AML.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead immunotherapeutic candidate, galinpepimut-S (GPS), targeting the WT1 protein in AML patients. The company is actively preparing for a potential Biologics License Application (BLA) following the final analysis of the REGAL study.
Expected impact: Establishment of a first-in-class maintenance therapy for AML patients in second complete remission who are ineligible for stem cell transplants.
Expanding the clinical development of SLS009, a highly selective CDK9 inhibitor, into first-line treatment. The initiative focuses on newly diagnosed AML patients with high-risk genetic mutations (such as ASXL1 and TP53) who are unlikely to benefit from standard venetoclax/azacitidine regimens.
Expected impact: Broadening the oncology pipeline beyond a single binary asset and addressing a significant unmet need in genetically defined, hard-to-treat AML populations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants 3D Medicines exclusive rights to develop and commercialize GPS and GPS+ across all therapeutic and diagnostic uses in the Greater China territory (mainland China, Hong Kong, Macau, and Taiwan).
Terms: SELLAS received a $7.5 million upfront license fee (with total upfront/milestones received reaching $10.5 million as of early 2024). The agreement includes up to $191.5 million in remaining potential development, regulatory, and sales milestones, plus tiered royalties on net sales ranging from high single to low double digits.
Grants SELLAS exclusive rights to develop, manufacture, and commercialize SLS009 (GFH009), a highly selective CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China.
Terms: SELLAS paid an initial upfront license and technology transfer fee of $10.0 million. The agreement includes up to $48.0 million in aggregate development and regulatory milestones for up to three indications, up to $92.0 million in sales-based milestones, and tiered royalties on annual net sales ranging from low to high single digits.